BIND Therapeutics, Inc. (NASDAQ:BIND) [Trend Analysis] released that it has selected to file a voluntary petition under Chapter 11 of the Bankruptcy Code in the U.S. Bankruptcy Court for the District of Delaware. The president and chief executive officer, BIND Therapeutics, Andrew Hirsch stated that they believe this decision is in best interests of firm and its stockholders.
The protections afforded by Chapter 11 provide for an orderly process and additional time that enables them to pursue strategic and financial alternatives that are in process. The filing minimizes impact from the recent demand by their lender, Hercules Technology III, L.P, for accelerated repayment of our outstanding loan. Their current cash and assets exceed the loan amount, and they are current on their regularly scheduled repayment obligations. Through this process, they expect to be able to maintain ongoing financing activities and collaborator obligations while moving our R&D initiatives and pipeline forward.
BIND Therapeutics, Inc. (NASDAQ:BIND) luring active investment momentum, shares a decrease -73.77% to $0.38. The total volume of 5.57 Million shares held in the session was surprisingly higher than its average volume of 103.99 shares. EPS estimates indicating constrictive facts, the current year from sell-side analysts, Price to current year EPS stands at 8.30%, and looking further price to next year’s EPS is 43.00%.
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) [Trend Analysis] released that it updates on EXPAREL (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the first quarter ended March 31, 2016. EXPAREL net product revenues were $63.8 million in the first quarter of 2016, compared to $56.0 million in the first quarter of 2015. Total revenues were $65.5 million in the first quarter of 2016, compared to $58.3 million in the first quarter of 2015.
Total operating expenses were $67.7 million in the first quarter of 2016, compared to $55.0 million in the first quarter of 2015.GAAP net loss was $3.9 million, or $(0.10) per share (basic and diluted), in the first quarter of 2016, compared to GAAP net income of $1.3 million, or $0.03 per share (basic and diluted), in the first quarter of 2015.
Several matter pinch shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX), as shares moving down -6.65% to $50.51 with a share volume of 2.81 Million. The stock is going forward its 52-week low with 41.17% and moving down from its 52-week high price with -37.86%. To have technical analysis views, liquidity ratio of a company was calculated 1.70 as evaluated with its debt to equity ratio of 0.49. The float short ratio was 19.53%, as compared to sentiment indicator; Short Ratio was 9.72.